Larson Financial Group’s Capricor Therapeutics CAPR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$9.27K Buy
979
+938
+2,288% +$10.4K ﹤0.01% 2553
2026
Q2
$987 Sell
41
-29
-41% -$879 ﹤0.01% 3318
2026
Q1
$2.13K Buy
+70
New +$1.86K ﹤0.01% 2942

Other funds holding CAPR

Larson Financial Group's CAPR Position: Q3 2026 in Review

Larson Financial Group increased its Capricor Therapeutics (CAPR) stake by 2,288% in Q3 2026, buying an estimated $10.4K and bringing the position to 979 shares worth $9.27K. The position accounts for ﹤0.01% of the portfolio, ranked #2553.

Larson Financial Group first reported a position in CAPR in Q1 2026 and has held it in 3 quarters since. 158 funds tracked by Wall St. Rank hold CAPR as of Q3 2026.

  • Larson Financial Group held 979 shares of Capricor Therapeutics worth $9.27K as of Q3 2026.
  • Larson Financial Group bought 938 Capricor Therapeutics shares in Q3 2026, an estimated $10.4K.
  • Capricor Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q3 2026, its #2553 holding.
  • Larson Financial Group first reported a position in Capricor Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • 158 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q3 2026.

Based on Larson Financial Group's 13F filing for Q3 2026, filed 5 Nov 2026.